. Author manuscript; available in PMC: 2015 Dec 15.

Published in final edited form as: Toxicol Appl Pharmacol. 2014 Oct 31;281(3):254–265. doi: 10.1016/j.taap.2014.10.009

Table 7.

Summary of Oximes Challenged with VX

Oxime Dose	Oxime	Oxime Dose (mg/kg)	24-hr Lethality	24-hr Mean QOL Score	24-hr Mean RA_AChE (%)	24-hr Mean RA_BChE (%)
Equimolar	2 PAM Cl	25.7	0/8^*	0.0^*	86^*	87^*
	MMB4 DMS	65.3	0/8^*	0.0^*	104^*	93^*
	HLö7 DMS	75.9	0/8^*	1.0^*	73^*	77
	TMB4	15.8	0/8^*	1.0	68^*	67
	Obidoxime	52.3	1/8^*	1.5	92^*	96^*
	HI-6 DMS	69.6	2/8	3.6^*	103^*	94^*
	MINA	12.7	2/8	3.8	49	64
	RS194B	31	4/8	7.0	53	57
	none	0.0	33/64 = 52%	6.9^†	46	62

Therapeutic	MMB4 DMS	104	0/8^*	0.3^*	96^*	97^*
	MINA	33.2	0/8^*	0.9^*	53	64
	HI-6 DMS	110	2/8	3.8	85^*	75^*
	RS194B	126	3/8	6.0	69^*	64
	none	0.0	17/32 = 53%	7.8^‡	44	52

Statistically significant at the 0.05 level compared to the control group

^†

pooled across 64 animals challenged as equimolar controls with VX

^‡

pooled across 32 animals challenged as TI controls with VX